Arabinosyladenine monophosphate in genital herpes: A double-blind, placebo-controlled study

Virgil A. Hatcher; Alvin E. Friedman-Kien; Edwin L. Marcus; Richard J. Klein

doi:10.1016/0166-3542(82)90051-1

Arabinosyladenine monophosphate in genital herpes: A double-blind, placebo-controlled study

Virgil A. Hatcher, Alvin E. Friedman-Kien, Edwin L. Marcus, Richard J. Klein

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

A double-blind, placebo-controlled study was performed in 55 male patients with recurrent herpes simplex genitalis. The 29 patients who received topical arabinosyladenine monophosphate (ara-AMP) showed no significant difference in viral shedding, duration of pain, healing time or development of new lesions as compared to 26 placebo-treated patients. Ara-AMP was well-tolerated when topically applied. Serum neutralizing antibody titers did not change significantly during the acute and convalescent periods of the patient's recurrent HSG attacks. We conclude that ara-AMP, when applied topically as a 10% gel five times a day within 24 h of onset of recurrent HSG, does not influence the virologic and clinical evolution of the recurrent episode.

Original language	English
Pages (from-to)	283-290
Number of pages	8
Journal	Antiviral Research
Volume	2
Issue number	5
DOIs	https://doi.org/10.1016/0166-3542(82)90051-1
State	Published - Oct 1982
Externally published	Yes

Keywords

arabinosyladenine monophosphate
double-blind, placebo-controlled study
genital herpes

Access to Document

10.1016/0166-3542(82)90051-1

Cite this

@article{17b8818c9a644fe8a5b1a7ad16a14492,

title = "Arabinosyladenine monophosphate in genital herpes: A double-blind, placebo-controlled study",

abstract = "A double-blind, placebo-controlled study was performed in 55 male patients with recurrent herpes simplex genitalis. The 29 patients who received topical arabinosyladenine monophosphate (ara-AMP) showed no significant difference in viral shedding, duration of pain, healing time or development of new lesions as compared to 26 placebo-treated patients. Ara-AMP was well-tolerated when topically applied. Serum neutralizing antibody titers did not change significantly during the acute and convalescent periods of the patient's recurrent HSG attacks. We conclude that ara-AMP, when applied topically as a 10% gel five times a day within 24 h of onset of recurrent HSG, does not influence the virologic and clinical evolution of the recurrent episode.",

keywords = "arabinosyladenine monophosphate, double-blind, placebo-controlled study, genital herpes",

author = "Hatcher, {Virgil A.} and Friedman-Kien, {Alvin E.} and Marcus, {Edwin L.} and Klein, {Richard J.}",

note = "Funding Information: This study was supported by Warner-Lambert Pharmaceutical Company. We wish to thank Eileen Brady and Eugene DeStefano for their technical assistance.",

year = "1982",

month = oct,

doi = "10.1016/0166-3542(82)90051-1",

language = "English",

volume = "2",

pages = "283--290",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier B.V.",

number = "5",

}

TY - JOUR

T1 - Arabinosyladenine monophosphate in genital herpes

T2 - A double-blind, placebo-controlled study

AU - Hatcher, Virgil A.

AU - Friedman-Kien, Alvin E.

AU - Marcus, Edwin L.

AU - Klein, Richard J.

N1 - Funding Information: This study was supported by Warner-Lambert Pharmaceutical Company. We wish to thank Eileen Brady and Eugene DeStefano for their technical assistance.

PY - 1982/10

Y1 - 1982/10

N2 - A double-blind, placebo-controlled study was performed in 55 male patients with recurrent herpes simplex genitalis. The 29 patients who received topical arabinosyladenine monophosphate (ara-AMP) showed no significant difference in viral shedding, duration of pain, healing time or development of new lesions as compared to 26 placebo-treated patients. Ara-AMP was well-tolerated when topically applied. Serum neutralizing antibody titers did not change significantly during the acute and convalescent periods of the patient's recurrent HSG attacks. We conclude that ara-AMP, when applied topically as a 10% gel five times a day within 24 h of onset of recurrent HSG, does not influence the virologic and clinical evolution of the recurrent episode.

AB - A double-blind, placebo-controlled study was performed in 55 male patients with recurrent herpes simplex genitalis. The 29 patients who received topical arabinosyladenine monophosphate (ara-AMP) showed no significant difference in viral shedding, duration of pain, healing time or development of new lesions as compared to 26 placebo-treated patients. Ara-AMP was well-tolerated when topically applied. Serum neutralizing antibody titers did not change significantly during the acute and convalescent periods of the patient's recurrent HSG attacks. We conclude that ara-AMP, when applied topically as a 10% gel five times a day within 24 h of onset of recurrent HSG, does not influence the virologic and clinical evolution of the recurrent episode.

KW - arabinosyladenine monophosphate

KW - double-blind, placebo-controlled study

KW - genital herpes

UR - http://www.scopus.com/inward/record.url?scp=0020373740&partnerID=8YFLogxK

U2 - 10.1016/0166-3542(82)90051-1

DO - 10.1016/0166-3542(82)90051-1

M3 - Article

C2 - 6185089

AN - SCOPUS:0020373740

SN - 0166-3542

VL - 2

SP - 283

EP - 290

JO - Antiviral Research

JF - Antiviral Research

IS - 5

ER -

Arabinosyladenine monophosphate in genital herpes: A double-blind, placebo-controlled study

Abstract

Keywords

Access to Document

Fingerprint

Cite this